| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 603259.CN | WuXi AppTec Co., Ltd. Class A | 84.7 | ¤63,790 | CN |
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 69.1 | ¤13,475 | CN |
| 002653.CN | Haisco Pharmaceutical Group Co. Ltd. Cla | 67.8 | ¤10,634 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 90.2 | ¤7,408 | CN |
| 688336.CN | Sunshine Guojian Pharmaceutical (Shangha | 86.0 | ¤5,703 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300515.CN | Hunan Sundy Science and Technology Co., | 72.6 | ¤472 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 55.4 | ¤526 | CN |
| 688410.CN | SWS Hemodialysis Care Co., Ltd. Class A | 67.0 | ¤541 | CN |
| 603998.CN | Hunan Fangsheng Pharmaceutical Co., Ltd. | 66.6 | ¤615 | CN |
| 300871.CN | Hvsen Biotechnology Co. Ltd. Class A | 67.8 | ¤655 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 002001.CN | Zhejiang NHU Co. Ltd. Class A | 69.1 | 21 | CN |
| 000423.CN | Dong-E-E-Jiao Co., Ltd. Class A | 70.7 | 20 | CN |
| 600285.CN | Henan Lingrui Pharmaceutial Co., Ltd. Cl | 73.1 | 10 | CN |
| 600867.CN | Tonghua Dongbao Pharmaceutical Co., Ltd. | 64.1 | 10 | CN |
| 002107.CN | Shandong Wohua Pharmaceutical Co., Ltd. | 55.4 | 8 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 68.4 | 8 | CN |
| 002603.CN | Shijiazhuang Yiling Pharmaceutical Co., | 62.2 | 6 | CN |
| 688578.CN | Shanghai Allist Pharmaceuticals Co. Ltd. | 90.2 | 6 | CN |
| 002437.CN | Harbin Gloria Pharmaceuticals Co., Ltd. | 62.7 | 5 | CN |
| 300206.CN | Edan Instruments, Inc. Class A | 66.3 | 5 | CN |
| Average Market Cap | ¤4,798 |
| Median Market Cap | ¤1,179 |
| Avg. 3 Mo. Dollar Vol. | ¤77,909,624 |
| Avg. 3 Mo. Trading Vol. | 15,040,532 |
| Last Rebalance Date | 06/15/2026 |
| Companies Replaced | 16 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 22.0 |
| Forward P/E Ratio (12 Mo.) | 20.2 |
| Price/Book Ratio | 3.3 |
| Avg. Revenue Chg. - 3 Yr | 52.0% |
| Avg. Op. Income Chg. - 3 Yr. | 64.8% |
| Avg. EPS Growth - 3 Yr. | 19.2% |
| Avg. EPS Growth - 1 Yr. | 12.9% |
| Avg. Operating Margin | 19.1% |
| Avg. LT Debt to Total Capital | 6.5% |
| Avg. Return on Equity | 15.8% |
| Dividend Yield | 1.4% |
| China Health Care Index | 66.3 |
| China | 100.0% |
